Literature DB >> 17377772

Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with alpha1beta2gamma2S subunits of GABA (A) receptors.

Danka Pericić1, Dubravka Svob Strac, Maja Jazvinsćak Jembrek, Josipa Vlainić.   

Abstract

Benzodiazepines are drugs known to produce tolerance and dependence and also to be abused and co-abused. The aim of this study was to further explore the mechanisms that underlie adaptive changes in GABA(A) receptors following prolonged exposure to these drugs. Human embryonic kidney (HEK 293) cells stably expressing recombinant alpha1beta2gamma2s GABA(A) receptors were exposed for 72 h to a high concentration of diazepam (50 microM) in the absence or presence of other drugs. Radioligand binding studies were used to determine the parameters of [(3)H]flunitrazepam and [(3)H]muscimol binding sites and allosteric interactions between these sites. Prolonged treatment with diazepam increased the maximum number (B (max)) of [(3)H]flunitrazepam and [(3)H]muscimol binding sites in the membranes, and of [(3)H]muscimol binding sites on the surface of HEK 293 cells. There was no change in the affinity (K (d)) of binding sites. The diazepam-induced increase in the B (max) value of [(3)H]flunitrazepam binding sites was reduced by two GABA(A) receptor antagonists, gabazine (1 and 10 microM) and picrotoxin (100 microM). In addition, it was reduced by cycloheximide (5 microg/ml), a protein synthesis inhibitor, and actinomycin D (7.5 microg/ml), an RNA synthesis inhibitor. Flumazenil (5 microM), the antagonist of benzodiazepine binding sites, also up-regulated [(3)H]flunitrazepam recognition sites. Simultaneous treatment with diazepam and flumazenil failed to produce an additive up-regulation. GABA (1 nM - 1 mM)-induced potentiation of [(3)H]flunitrazepam binding to membranes obtained from diazepam (50 microM)-pretreated cells was markedly reduced, suggesting functional uncoupling between GABA and benzodiazepine binding sites. The results suggest that diazepam up-regulated benzodiazepine binding sites on stably expressed GABA(A) receptors by stimulating their synthesis at both the transcriptional and translational levels. A comparable increase of [(3)H]muscimol binding sites expressed on the surface of intact HEK 293 cells suggests that internalisation of surface receptors presumably can not explain the uncoupling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17377772     DOI: 10.1007/s00210-007-0152-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  50 in total

1.  Tolerance to diazepam and changes in GABA(A) receptor subunit expression in rat neocortical areas.

Authors:  C Pesold; H J Caruncho; F Impagnatiello; M J Berg; J M Fritschy; A Guidotti; E Costa
Journal:  Neuroscience       Date:  1997-07       Impact factor: 3.590

Review 2.  International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.

Authors:  E A Barnard; P Skolnick; R W Olsen; H Mohler; W Sieghart; G Biggio; C Braestrup; A N Bateson; S Z Langer
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

3.  Molecular dissection of benzodiazepine binding and allosteric coupling using chimeric gamma-aminobutyric acidA receptor subunits.

Authors:  A J Boileau; A M Kucken; A R Evers; C Czajkowski
Journal:  Mol Pharmacol       Date:  1998-02       Impact factor: 4.436

4.  Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms.

Authors:  N J Ali; R W Olsen
Journal:  J Neurochem       Date:  2001-12       Impact factor: 5.372

Review 5.  Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal.

Authors:  A N Bateson
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

6.  Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA(A) receptors supports an allosteric model of modulation.

Authors:  Scott S Downing; Yan T Lee; David H Farb; Terrell T Gibbs
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

7.  Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates.

Authors:  James K Rowlett; Donna M Platt; Snjezana Lelas; John R Atack; Gerard R Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

8.  Gamma-aminobutyric acidA receptor function is desensitised in rat cultured cerebellar granule cells following chronic flunitrazepam treatment.

Authors:  M J Brown; M D Wood; M C Coldwell; D R Bristow
Journal:  J Neurochem       Date:  1998-09       Impact factor: 5.372

9.  Prolonged exposure to gamma-aminobutyric acid up-regulates stably expressed recombinant alpha 1 beta 2 gamma 2s GABAA receptors.

Authors:  Danka Pericić; Dubravka Svob Strac; Maja Jazvinsćak Jembrek; Ivana Rajcan
Journal:  Eur J Pharmacol       Date:  2003-12-15       Impact factor: 4.432

10.  Serum diazepam concentrations in overdose. Their significance.

Authors:  P Jatlow; K Dobular; D Bailey
Journal:  Am J Clin Pathol       Date:  1979-10       Impact factor: 2.493

View more
  8 in total

1.  The effects of zolpidem treatment and withdrawal on the in vitro expression of recombinant alpha1beta2gamma2s GABA(A) receptors expressed in HEK 293 cells.

Authors:  Josipa Vlainić; Maja Jazvinsćak Jembrek; Dubravka Svob Strac; Danka Pericić
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-23       Impact factor: 3.000

2.  Differential effects of short- and long-term zolpidem treatment on recombinant α1β2γ2s subtype of GABA(A) receptors in vitro.

Authors:  Josipa Vlainić; Maja Jazvinšćak Jembrek; Toni Vlainić; Dubravka Švob Strac; Danka Peričić
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

3.  Training-induced changes in the expression of GABAA-associated genes in the amygdala after the acquisition and extinction of Pavlovian fear.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  Eur J Neurosci       Date:  2007-12       Impact factor: 3.386

4.  Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?

Authors:  Christiaan H Vinkers; Berend Olivier
Journal:  Adv Pharmacol Sci       Date:  2012-03-29

5.  GABAergic alterations in neocortex of patients with pharmacoresistant temporal lobe epilepsy can explain the comorbidity of anxiety and depression: the potential impact of clinical factors.

Authors:  Luisa Rocha; Mario Alonso-Vanegas; Iris E Martínez-Juárez; Sandra Orozco-Suárez; David Escalante-Santiago; Iris Angélica Feria-Romero; Cecilia Zavala-Tecuapetla; José Miguel Cisneros-Franco; Ricardo Masao Buentello-García; Jesús Cienfuegos
Journal:  Front Cell Neurosci       Date:  2015-01-05       Impact factor: 5.505

6.  Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors.

Authors:  Hana Kubová; Zdeňka Bendová; Simona Moravcová; Dominika Pačesová; Luisa Rocha; Pavel Mareš
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 7.  Probiotics as an Adjuvant Therapy in Major Depressive Disorder.

Authors:  Josipa Vlainić Vlainić; Jelena Šuran; Toni Vlainić; Antonella Letizia Vukorep
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 8.  Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.

Authors:  Predrag Sikiric; Sven Seiwerth; Rudolf Rucman; Danijela Kolenc; Lovorka Batelja Vuletic; Domagoj Drmic; Tihomir Grgic; Sanja Strbe; Goran Zukanovic; Dalibor Crvenkovic; Goran Madzarac; Iva Rukavina; Mario Sucic; Marko Baric; Neven Starcevic; Zoran Krstonijevic; Martina Lovric Bencic; Igor Filipcic; Dinko Stancic Rokotov; Josipa Vlainic
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.